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lage. Tissue recombination experiments
have provided evidence that surrounding
neural tissues are a source of inductive sig-
nals for determination of the primordium
(14). Formation of the pouch rudiment does
not require the function of either Lhx3 or
Lhx4 (Fig. 4, arrow a). Lhx3 or Lhx4 controls
development of the pouch rudiment into a
definitive pouch (Fig. 4, arrow b). Commit-
ment of precursor cells in Rathke’s pouch to
a pituitary organ fate is controlled by Lhx3
(Fig. 4, arrow c). From E12.5 onward, cells
begin to express lineage-specific molecules.
Lhx4 is required for proliferation of lineage
precursors. In the Lhx32/2 mutant, pouch
development is arrested before the appear-
ance of most pituitary cell lineages (7), pre-
cluding an exhaustive evaluation of Lhx3
function in lineage development. However,
Lhx3 regulates the expression of Pit-1, GSU,
and, in synergy with Pit-1, GH and prolactin
(PRL) in vitro (7, 15), suggesting that Lhx3
also regulates cellular differentiation (Fig. 4,
arrow d). Because Lhx3 is expressed in almost
all pituitary precursor cells, it is unlikely that
this gene determines cell type identity. Rath-
er, it may act in concert with genes that are
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Requirement of NF-kB Activation to Suppress
p53-Independent Apoptosis Induced by
Oncogenic Ras
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The ras proto-oncogene is frequently mutated in human tumors and functions to chron-
ically stimulate signal transduction cascades resulting in the synthesis or activation of
specific transcription factors, including Ets, c-Myc, c-Jun, and nuclear factor kappa B
(NF-kB). These Ras-responsive transcription factors are required for transformation, but
the mechanisms by which these proteins facilitate oncogenesis have not been fully
established. Oncogenic Ras was shown to initiate a p53-independent apoptotic re-
sponse that was suppressed through the activation of NF-kB. These results provide an
explanation for the requirement of NF-kB for Ras-mediated oncogenesis and provide
evidence that Ras-transformed cells are susceptible to apoptosis even if they do not
express the p53 tumor-suppressor gene product.
Mutations in a ras allele occur in 30% of
all human tumors (1), making ras the most
widely mutated human proto-oncogene.
Both mitogen-activated protein (MAP) ki-
nase–dependent and MAP kinase–inde-
pendent pathways mediate Ras-induced cel-
lular responses (2), and these signal trans-
duction pathways ultimately control the ac-
tivity of various transcription factors (3).
The Ets, c-Myc, and c-Jun proteins are Ras-
responsive transcription factors required for
cellular transformation in vitro (4) and in
vivo (5). The transcription factor NF-kB is
also activated in response to oncogenic Ras
(6), and this regulation occurs largely
through the stimulation of the transcrip-
tional function of the NF-kB RelA/p65 sub-
unit (7). Moreover, NF-kB is required for
Ras-mediated focus-forming activity (7),
and activation of this transcription factor
provides protection against apoptosis (8, 9).
Because NF-kB may play a direct role in
cellular transformation (10) and because
oncogenesis appears to require an anti-ap-
optotic function (11), we investigated
whether oncogenic Ras requires NF-kB ac-
tivation to block transformation-induced
programmed cell death.
To determine whether the inhibition of
NF-kB in Ras-transformed cells would ini-
tiate a cell death response, we used b-galac-
tosidase (b-Gal) expression assays to mea-
sure cell viability. We inhibited NF-kB ac-
tivity with a super-repressor form of IkBa
(SR-IkBa), which cannot be phosphoryl-
ated (12) or degraded (13) and, therefore,
blocks the nuclear translocation and subse-
quent transactivation of NF-kB –responsive
genes (8). Parental NIH 3T3 and H-Ras–
transformed cells (3T3 H-Ras[V12]) were
cotransfected with a pCMV-LacZ reporter
and with either an empty expression vector
control or a vector encoding SR-IkBa. H-
Ras–transformed NIH 3T3 cells expressing
SR-IkBa displayed a decrease in the total
number of b-Gal–positive cells as compared
with cells transfected with the vector con-
trol (Fig. 1). In contrast, parental NIH 3T3
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cells expressing SR-IkBa showed no reduc-
tion in the number of b-Gal–positive cells,
indicating that the expression from the
pCMV-lacZ reporter was not affected by
the super-repressor and that expression of
IkBa did not kill nontransformed parental
cells (Fig. 1). Similar results were obtained
with H-Ras(V12)–transformed Rat-1 fibro-
blasts and C127 mouse mammary epithelial
cells (14). Because gain-of-function muta-
tions in either K- or N-ras are more preva-
lent in human cancers than are mutations
in H-ras (1), we examined whether NF-kB
served a similar protective role for other
oncogenic Ras proteins. Like 3T3 H-
Ras(V12) cells, NIH 3T3 cells transformed
with other activated alleles of ras died after
the expression of SR-IkBa (Fig. 1). Non-
transformed NIH 3T3 cells stably express-
ing wild-type H-Ras did not exhibit a loss of
cell viability in the presence of the SR-
IkBa (14). These results indicate that on-
cogenic Ras (but not wild-type H-Ras) re-
quires the cell survival function of NF-kB
to overcome the activation of a death path-
way initiated in transformed cells.
To determine whether the loss of cell
viability was a direct effect of oncogenic
Ras, we used the Rat-1:iRas cell line, which
contains a stably integrated oncogenic H-
ras(V12) gene under the controlled expres-
sion of an isopropyl-b-D-thiogalactopyrano-
side (IPTG)–inducible promoter (15). To
inhibit NF-kB activation, we established
the Rat-1:iRasI line, which constitutively
expresses SR-IkBa. Moreover, a control
line was established, Rat-1:iRasV, that con-
tains the empty expression vector. The ad-
dition of IPTG induced similar amounts of
p21ras protein in each of the cell lines,
whereas only the Rat-1:iRasI cells displayed
a larger immunoreactive band that corre-
sponded to the Flag-tagged SR-IkBa (Fig.
2A). In contrast with the Rat-1:iRasV con-
trol cells, the Rat-1:iRasI line did not dem-
onstrate increased nuclear NF-kB binding
activity or increased transactivation of the
3x-kB–dependent reporter in response to
Fig. 1. Effects of SR-IkBa expression in parental
and Ras-transformed NIH 3T3 cells. Parental
NIH 3T3 and Ras-transformed NIH 3T3 cells
were cotransfected (8) with pCMV-LacZ
(pcDNA3-LacZ, Invitrogen; 0.2 mg per 24-well
plate) and either an empty expression vector
control (CMV-4) or with vector encoding SR-
IkBa (1 mg per plate each). After 48 hours cells
were fixed and stained with X-Gal, and b-Gal–
positive cells were counted in each well. The
results represent the mean 6 SD of three inde-
pendent experiments performed in triplicate.
Fig. 2. Apoptotic effects of
Ras in Rat-1 cells expressing
SR-IkBa. (A) Generation and
characterization of the Rat-1:
iRas cell line expressing SR-
IkBa. Rat-1:iRas cells, con-
taining an IPTG-inducible H-
Ras( V12) cDNA (15), were
transfected with the empty
expression vector (pCMV-4)
or with pCMV-4 containing a
cDNA encoding SR-IkBa (1
mg each) and with pBabe-
puro (0.2 mg), which provid-
ed puromycin resistance at a
concentration of 1 mg/ml.
The Rat-1:iRasV line con-
tains the empty expression
vector, whereas the Rat-1:
iRasI line expresses the su-
per-repressor form of IkBa.
Parental Rat-1:iRas and V
and I cells were treated with 5 mM IPTG (Promega) for 24 hours, and protein expression was assessed by
protein immunoblotting total cell extracts (60 mg per lane) with either a pan-Ras antibody (Ab-4, Calbio-
chem) or with an antibody specific for IkBa (Rockland). (B) Expression of oncogenic Ras and SR-IkBa.
Rat-1:iRasI and Rat-1:iRasV cells (1 3 106) were plated into 100-mm dishes containing Dulbecco’s
modified Eagle’s medium (DMEM) 1 10% fetal bovine serum (FBS), and 12 hours later cells were either left
untreated or stimulated with 5 mM IPTG. Cells were harvested at the time indicated, and viable cells were
identified by trypan blue dye exclusion. The data represent the mean (SD # 2.7) of three independent
experiments. (C) Apoptosis in Rat-1 cells expressing the SR-IkBa and H-Ras( V12). Micrographs (mag-
nification, 320) of Rat-1:iRasV and Rat-1:iRasI cells grown in DMEM containing 10% FBS in the absence
or presence of IPTG for 36 hours. Dying, nonadherent cells are seen as refractile by phase contrast at this
magnification. (D) DNA fragmentation in the absence of NF-kB activation. Rat-1:iRasI and Rat-1:iRasV
cells were cultured at 1 3 105 cells/ml in DMEM containing 10% FBS in the absence or presence of IPTG.
After 36 hours, cells were harvested, and genomic DNAs were isolated and resolved on 1.5% agarose gel.
Representative DNAs include (lane 1) Rat-1:iRasV, (lane 2) Rat-1:iRasV 1 IPTG, (lane 3) Rat-1:iRasI, and
(lane 4) Rat-1:iRasI 1 IPTG. Linear double-stranded DNA fragments were sized by means of a 1-kb DNA
ladder (Gibco-BRL).
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the expression of oncogenic Ras or tumor
necrosis factor stimulation (14).
We used the Rat-1:iRasI cells to deter-
mine if the activation of Ras leads to a loss of
cell viability under conditions where NF- kB
is inhibited. Rat-1:iRasI and control cells
were subjected to IPTG treatment, and total
cell numbers were examined over a 3-day
period. Greater than a 50% loss in cell via-
bility was observed in the Rat-1:iRasI cells
after Ras expression, as compared with the
vector control cells (Fig. 2B). Similar results
were obtained when five individual puromy-
cin-resistant clones, expressing similar levels
of the IkBa transgene, were pooled and an-
alyzed (14). Both the Rat-1:iRasV and Rat-
1:iRasI cells displayed distinct Ras-trans-
formed morphology after the addition of
IPTG (Fig. 2C) (15). Cell death induced by
oncogenic Ras expression in Rat-1:iRasI
cells bore the consistent hallmarks of apo-
ptosis (16), including retraction of cellular
processes, nuclear condensation, and a loss of
adherence to the tissue culture dish (Fig.
2C). Induced expression of activated Ras in
Rat-1:iRasI cells, but not the vector control
cells, resulted in an increase in genomic
DNA fragmentation evident 36 hours after
the addition of IPTG, as detected by agarose
gel electrophoresis (Fig. 2D). Furthermore,
IPTG treatment induced apoptosis, as de-
tected by the appearance of deoxynucleoti-
dyl transferase-mediated dUTP nick-end la-
beling (TUNEL)–positive cells (14). Fluo-
rescence-activated cell sorter (FACS) anal-
ysis of propidium iodide- and bromodeoxy-
uridine-stained cells confirmed that IPTG
did not induce senescence (17) and that the
cells that were ,2N DNA represented apo-
ptotic cells and not necrotic cells (14). Thus,
the induction of oncogenic Ras expression in
the presence of a specific inhibitor of NF- kB
leads to enhanced apoptosis. Our results sup-
port the hypothesis that oncogenic Ras re-
quires NF-kB activation to block transfor-
mation-induced programmed cell death.
The inability of activated Ras to trans-
form primary cells is due, in part, to the
expression of tumor-suppressor genes, such as
p53 (18) and p16 (19). To determine if p53
had a role in the Ras-dependent killing, we
examined whether p532/2 mouse embryo
fibroblasts (MEFs) expressing oncogenic H-
Ras(V12) required the cell survival function
of NF-kB. We used p532/2 MEFs expressing
either E1A, a viral oncogene product that
activates NF-kB (20), or E1A plus H-Ras
(21). The cells expressing E1A or E1A and
H-Ras displayed enhanced NF-kB–depen-
dent transcriptional activity, as compared
with that in control p532/2 MEFs (14).
Moreover, the total number of p532/2 MEFs
expressing E1A or both E1A and H-Ras was
reduced after the expression of SR-IkBa
(Fig. 3A). In contrast, p532/2 MEFs showed
little loss of viability after expression of the
super-repressor form of IkB (Fig. 3A). Al-
though E1A induces apoptosis in a p53-
dependent manner (22), our data indicate
that E1A can also induce apoptosis in a
p532/2-deficient background if the protec-
tive function of NF-kB is inhibited. To con-
firm that E1A was not required for Ras-
mediated killing, we transfected p532/2
MEFs with pCMV-LacZ, H-Ras(V12), and
with either the empty expression vector or
vector encoding SR-IkBa. p532/2 MEFs
transfected with oncogenic H-Ras(V12), but
not wild-type H-Ras, were effectively killed
after inactivation of NF-kB by SR-IkBa
(Fig. 3B). Our results indicate that p53 null
cells can be effectively transformed by Ras
because this oncogene activates NF-kB to
suppress apoptosis.
To examine whether both p53-depen-
dent and -independent mechanisms were
operative in the Ras-induced apoptosis, we
used the mutant p53135 protein, which
functions as a dominant negative inhibitor
of endogenously expressed wild-type p53
protein (23). Because p53 is wild-type in
NIH 3T3 cells (24), it is possible that p53
contributed to cell death after the expres-
sion of oncogenic Ras and SR-IkBa (Fig.1).
Parental NIH 3T3 cells were cotransfected
with pCMV-LacZ, together with either the
vector control (pLTR) or pLTR-p53135, and
with either the CMV-4 control vector or
the SR-IkBa vector. The dominant nega-
tive p53135 mutant did not inhibit oncogen-
ic Ras–mediated killing after the inactiva-
tion of NF-kB (Fig. 3C). The p53135 mu-
tant appeared to be functional because it
inhibited p53-dependent gene expression in
NIH 3T3 cells after doxorubicin treatment
(14) and because it blocked p53-dependent
apoptosis (25). These results indicate that
NF-kB activity is required to inhibit p53-
independent programmed cell death medi-
ated by oncogenic Ras.
Our data indicate that oncogenic Ras
elicits both pro- and anti-apoptotic path-
ways, with the latter pathway being domi-
Fig. 3. Ras-mediated apoptosis in cells lacking p53. (A) Requirement of NF-kB in E1A and E1A plus
H-Ras( V12)–transformed p532/2 fibroblasts for cell survival. p532/2 MEFs (passage 5) and p532/2
MEFs transformed with either E1A or E1A plus activated H-Ras( V12) were transfected with the pCMV-
LacZ (0.2 mg) and with the empty vector control, or with the SR-IkBa (1 mg each per 24-well plate). After
48 hours cells were fixed and then stained, and b-Gal–expressing cells were counted. The data are
representative of three independent experiments performed in triplicate. (B) Ras-mediated p53-inde-
pendent cell killing. p532/2 MEFs were transfected with the pCMV-LacZ together with either the empty
expression vector control or with the various expression constructs indicated. Cells were stained for
b-Gal activity 48 hours after transfection. Data are shown as the mean 6 SD and are representative of
two experiments performed in triplicate. (C) Failure of dominant negative p53 to prevent oncogenic
Ras–mediated killing after inactivation of NF-kB. Parental NIH 3T3 cells were transfected with the
pCMV-LacZ together with either the vector control (pLTR) or with pLTR-p53135, which encodes the
dominant negative p53 mutant. Additionally, cells were transfected with either the empty expression
vector control (pCMV-4) or with SR-IkBa. b-Gal expression assays were performed. Data are shown as
the mean 6 SD of two independent experiments performed in triplicate. Bars are shaded as in (A).










nant in immortalized rodent cells. Consis-
tent with this idea, Ras has been shown to
induce programmed cell death (26) and to
suppress apoptosis induced by Myc and E1A
(27, 28). Our studies demonstrate that the
ability of activated Ras to transform p53
null cells is dependent on the ability of this
oncogene to activate NF-kB. Thus, there
are cell death pathways (independent of
p53) that can be initiated by the Ras onco-
gene after the inactivation of NF-kB. Ad-
ditional studies indicate that the cell killing
induced by Ras is independent of Raf-1 and
its signaling cascade (14). Consistent with
this notion, we found that 3T3 R-Ras(V38)
cells were killed equally as well as 3T3
H-Ras(V12) cells after expression of the
SR-IkBa construct (Fig. 1). Because R-Ras
does not interact with the serine-threonine
Raf-1 kinase (29), this is consistent with
the hypothesis that Raf is not involved in
Ras-mediated killing after NF-kB inactiva-
tion. Our data demonstrate that oncogenic
Ras elicits an apoptotic pathway that is
suppressed by the parallel activation of NF-
kB. Because a complex array of anti-apop-
totic proteins are expressed in tumors, the
activation of NF-kB by Ras mutation may
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